Beauvericin ameliorates experimental colitis by inhibiting activated T cells via downregulation of the PI3K/Akt signaling pathway (Q28536748)
Jump to navigation
Jump to search
scientific article (publication date: 2013)
Language | Label | Description | Also known as |
---|---|---|---|
English | Beauvericin ameliorates experimental colitis by inhibiting activated T cells via downregulation of the PI3K/Akt signaling pathway |
scientific article (publication date: 2013) |
Statements
Beauvericin ameliorates experimental colitis by inhibiting activated T cells via downregulation of the PI3K/Akt signaling pathway (English)
0 references
2013
0 references
8
0 references
12
0 references
e83013
0 references
10 December 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference